Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alamar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alamar Biosciences's regulatory disclosures and financial reporting.
Illumina Innovation Fund entities and director Nicholas Naclerio report a significant ownership stake in Alamar Biosciences, Inc. common stock. They are deemed to beneficially own 6,363,612 shares, representing 9.6% of Alamar’s common stock outstanding after its initial public offering.
The position arises from multiple preferred stock investments since 2020, an aggregate $8,927,259.98 in convertible promissory notes, and an IPO purchase of 235,294 shares of common stock at $17.00 per share for $3,999,998.00. All shares were acquired using investment funds from Illumina Innovation Fund II and III investors.
The funds describe their holdings as for general investment purposes and may increase or decrease their position depending on market and company conditions. Illumina Innovation Fund II and III are subject to a 180‑day lock-up agreement after the IPO underwriting agreement, limiting near-term sales of their Alamar shares. Naclerio also serves on Alamar’s board and may receive additional equity compensation under the company’s 2026 equity incentive and director compensation plans.
Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates report a 6.3% beneficial stake in Alamar Biosciences, Inc. following its initial public offering. They directly hold 4,230,926 shares of common stock, acquired through Series C preferred conversion, a convertible note conversion, and a 300,000-share IPO purchase at $17 per share.
The investors state they hold the shares for investment purposes and may buy or sell more depending on business and market conditions. Their holdings are subject to registration rights, a prior waiver for the IPO registration, and a 180-day lock-up that runs through October 13, 2026.
Alamar Biosciences, Inc. reported that investment vehicles affiliated with Qiming converted multiple series of preferred stock into equity tied to its initial public offering. Qiming-related funds converted Series A-3, Series A-4, Series B and Series C preferred stock into Class B Common Stock, and each Class B share was then automatically reclassified into Common Stock immediately before the IPO.
All transactions were indirect, recorded at a price of $0.00 per share, and coded as conversions or other internal restructurings rather than market purchases or sales. The Qiming general partner entities may be deemed to share voting and dispositive power but disclaim beneficial ownership beyond their proportionate economic interest.
Alamar Biosciences, Inc. reported insider activity by entities affiliated with the Illumina Innovation Funds around its initial public offering. On April 20, 2026, these reporting persons completed an open‑market purchase of 235,294 shares of Common Stock at $17.00 per share, held indirectly, bringing one reported Common Stock position to 507,076 shares following the transaction.
At the same time, multiple convertible promissory notes and series of Preferred Stock automatically converted into Class B Common Stock, and each share of Class B Common Stock was then reclassified into one share of Common Stock in connection with the IPO. These conversions and a related reclassification moved millions of shares from preferred and Class B instruments into Common Stock, leaving no remaining balance in the reported derivative securities.
The securities are held by Illumina Innovation Fund II, L.P. and Illumina Innovation Fund III, L.P., whose general partners and sole managing member, director Nicholas Naclerio, may be deemed to have voting and investment power but each disclaims beneficial ownership except to any pecuniary interest.
Alamar Biosciences director Rebecca Chambers reported an internal restructuring of stock options, not an open-market trade. One option covering 140,612 shares of Common Stock at an exercise price of $7.60 per share is now recorded as outstanding, while a corresponding option tied to 140,612 shares of Class B Common Stock was removed.
Each share of Class B Common Stock was reclassified into one share of Common Stock immediately before the company’s initial public offering, and the option reflects that change. Twenty-five percent of the option vests on January 15, 2027, with the remaining shares vesting in equal monthly installments over the following three years, and the option expires on January 14, 2036.
Alamar Biosciences director Frank Witney reported internal option restructurings related to the company’s share reclassification. On April 20, 2026, six Form 4 transactions with code J moved stock options between underlying Class B Common Stock and Common Stock at no transaction price.
The filing shows options for 124,069 shares at an exercise price of $7.60 expiring on January 14, 2036, 33,085 shares at $3.10 expiring on April 15, 2035, and 49,627 shares at $0.59 expiring on April 20, 2031. A footnote states each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering.
Alamar Biosciences President Timothy Ogden White reported equity awards and restructuring of his holdings in connection with the company’s initial public offering. On April 20, 2026, he received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing his direct Common Stock holdings to 491,803 shares.
The filing also shows multiple Class B Common Stock and related stock options being reclassified into equivalent Common Stock immediately prior to completion of the IPO, with no cash changing hands. Separately, on April 16, 2026, he was granted a stock option for 163,358 shares of Common Stock at an exercise price of $17.00 per share, vesting over time beginning in 2027.
Alamar Biosciences Chief Operating Officer Shiping Chen reported equity compensation grants and pre‑IPO share conversions, with no open‑market buying or selling. Chen received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing direct Common Stock holdings to 760,105 shares after the award.
The filing also shows automatic conversions of Class A Common Stock, Founders Preferred Stock, Series A‑1 Preferred Stock and Class B Common Stock into Common Stock immediately before Alamar’s IPO, plus administrative reclassifications of related stock options. Chen was granted a new stock option over 163,358 shares at $17.00 per share, alongside existing options with lower exercise prices.
Alamar Biosciences CEO Yuling Luo reported a series of equity restructurings and awards around the company’s initial public offering. Several classes of preferred and Class A shares automatically converted into Class B Common Stock and were then reclassified into Common Stock immediately before the IPO, with no cash changing hands.
The filing also shows a grant of 76,509 restricted stock units that vest monthly, and a new stock option for 341,191 shares of Common Stock at an exercise price of $17.00 per share, vesting over four years. Many option entries reflect technical reclassifications between Class B Common Stock and Common Stock rather than market trades.